Combination Therapies for Cardiovascular-Kidney Risk Optimization: Who, When, and How?
Back to course
Video Transcription
Video Summary
Asset Caption
Janani Rangaswami, MD
Meta Tag
Speaker Janani Rangaswami
Keywords
cardiorenal-metabolic disease
type 2 diabetes
chronic kidney disease
SGLT2 inhibitors
finerenone
combination therapy